Bexarotene
Bexarotene (Targretin) is a vitamin A-like capsule and gel for the skin disease of cutaneous T-cell lymphoma when other treatments have stopped working.
Overview
Bexarotene is a synthetic retinoid selective for the retinoid X receptor. The FDA approved the capsules in December 1999 and the 1% gel in 2000 for cutaneous manifestations of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome) refractory to at least one prior systemic therapy, on two open-label historically controlled trials in 152 patients. The EU authorised Targretin capsules in 2001 for the same population. Central hypothyroidism and marked hypertriglyceridaemia are expected effects of RXR activation and need thyroid replacement and lipid-lowering therapy alongside treatment; it is teratogenic.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 1999 | Cutaneous manifestations of cutaneous T-cell lymphoma refractory to at least one systemic therapy |
| EU | 2001 | Skin manifestations of advanced-stage CTCL refractory to at least one systemic treatment |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Notes
top- Cutaneous T-cell lymphoma has no cancer record yet; link when one exists.
Latest papers
topQuery for this drug: (TITLE:"Bexarotene" OR ABSTRACT:"Bexarotene" OR TITLE:"Targretin" OR ABSTRACT:"Targretin") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Bexarotene, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductImiquimod
Shares Bausch Health and the tag nci-list.
- ProductMethylnaltrexone
Shares Bausch Health and the tag nci-list.